Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim

por Korn, E L, McShane, L M, Troendle, J F, Rosenwald, A, Simon, R
Publicado 2002

REporting recommendations for tumour MARKer prognostic studies (REMARK)

por McShane, L M, Altman, D G, Sauerbrei, W, Taube, S E, Gion, M, Clark, G M
Publicado 2005

Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival

por Rotunno, M, Zhao, Y, Bergen, A W, Koshiol, J, Burdette, L, Rubagotti, M, Linnoila, R I, Marincola, F M, Bertazzi, P A, Pesatori, A C, Caporaso, N E, McShane, L M, Wang, E, Landi, M T
Publicado 2010

Epstein–Barr virus microRNAs and lung cancer

por Koshiol, J, Gulley, M L, Zhao, Y, Rubagotti, M, Marincola, F M, Rotunno, M, Tang, W, Bergen, A W, Bertazzi, P A, Roy, D, Pesatori, A C, Linnoila, I, Dittmer, D, Goldstein, A M, Caporaso, N E, McShane, L M, Wang, E, Landi, M T
Publicado 2011

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from...

por Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.
Publicado 2021

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

por Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.
Publicado 2022